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Prevention of further cardiovascular events in patients
with established coronary heart disease is a priority for
public health.1 Previous studies have addressed such
issues and have showed that there is considerable room
for improvement.2–4 The Healthwise survey was con›
ducted in primary care throughout Britain to identify
the prevalence of recorded coronary disease and to
examine whether progress had been made in secondary
preventive measures. Smoking, blood pressure, record›
ing of cholesterol concentrations, and the specific use of
the four lifesaving classes of cardiac drugs—aspirin, â
blockers, angiotensin converting enzyme inhibitors, and
statins—were studied. (Other lifestyle issues, such as
dietary assessment and exercise, were variably noted in
practice records and are not shown.)
Participants, methods, and results
Practices that had computerised records but had not
recently undergone an audit of coronary heart disease
were identified from the Pharbase national registry of
general practices (IMS Health Strategic Technologies,
Loughborough). A total of 653 general practitioners
were invited to take part; 548 accepted. Twelve research
nurses joined these practices for about four weeks
between March 1997 and August 1998. Patients with
established coronary disease were identified from
practice records and the recording of risk factors and
secondary preventive measures was noted.
The mean list size was 7220, with an average of four
doctors in each practice. The total practice population
was 989 161, representing 1.7% of the population of
England, Scotland, and Wales. A total of 24 431
patients had a diagnosis of coronary disease, a
prevalence of 45 patients per doctor. The mean age of
men was 67 years and that of women was 72. Two
thirds of the patients were aged 60›80. The table shows
the prevalence of risk factors and secondary preventive
drug treatment.
Comment
The Healthwise survey shows that even in well
organised general practices there is ample scope for
improvement in the detection, recording, and interven›
tion of the major cardiac risk factors among patients
with established coronary heart disease. This is the
largest survey of secondary prevention of coronary
disease in UK general practice in recent years. It may
have a bias, representing larger practices with compu›
terised systems in place by 1997.
Several issues are notable. The prevalence of
coronary disease was 2.5% in the study; in Britain it is
3›7%. The discrepancy reflects the incomplete data in
primary care records. These “lost” individuals are
unlikely to receive optimal secondary preventive meas›
ures. Patients with established disease in our study were
predominantly 60›80 years old, reflecting the ageing
and increased survival of the UK population.
Of risk factors in patients with established coronary
disease, stopping smoking is the most important action
any person can make, yet almost a quarter of the total
study population still smoke. Control of blood pressure
is reasonably good among people without diabetes,
with about two thirds of the overall study population
having blood pressure below 160/90 mm Hg. How›
ever, blood pressure is less well managed among
diabetic patients. We now know that management of
blood pressure is at least as important as good control
of blood glucose, and better control in these high risk
patients is needed.
Lipids were much less well managed than blood
pressure. Most patients were hypercholesterolaemic or
had never been tested. Only a few were taking statins,
despite evidence that these drugs are effective. It is also
disappointing that so few patients with a previous myo›
cardial infarction were receiving â blockers, drugs that
are proved to reduce ventricular tachycardia and sudden
death after a heart attack. It is encouraging that about
half of the patients with heart failure in this study were
prescribed angiotensin converting enzyme inhibitors.
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Major modifiable risk factors and prescription of secondary preventive drug treatment in
24 431 patients with a diagnosis of coronary disease from 548 UK practices. Values are
numbers (percentages) of patients
Men (n=14 533) Women (n=9898)
Risk factor
Continued smoking 3783 (26) 1939 (20)
Diabetes mellitus 1589 (11) 1055 (11)
Hypertension (>160/90 mm Hg) 5407 (37) 4483 (35)
Diabetic patients (n=2644) 636/1589 (56) 591/1055 (56)
Cholesterol never recorded 5114 (35) 5112 (52)
Total cholesterol >5 mmol/l 6830 (47) 3977 (40)
Preventive drug treatment
Aspirin 7728 (53) 4505 (46)
â blockers 3303 (23) 1927 (19)
Previous myocardial infarction (n=10 164) 1750/7143 (24) 625/3021 (21)
Angiotensin converting enzyme inhibitors 2073 (14) 1207 (12)
Congestive heart failure (n=715) 245/443 (55) 124/272 (46)
Statins 2634 (18) 1315 (13)
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